Core Viewpoint - The Chinese traditional medicine sector is experiencing increased activity due to a surge in flu cases, with the Chinese Medicine ETF (560080) showing a slight decline but still attracting investor interest [1][9]. Market Performance - The Chinese Medicine ETF (560080) closed down 0.91% today, remaining in a consolidation phase, with a trading volume exceeding 84 million yuan, a 7% increase from the previous trading day [1]. - The ETF's closing premium rate was 0.06%, indicating ongoing investor attention, with two out of the last five days seeing inflows [1]. - The ETF's latest scale reached 2.598 billion yuan, leading its peers in the same category [1]. Stock Performance - Most constituent stocks of the Chinese Medicine ETF closed in the red, with notable declines including: - Pianzaihuang down 1.59% to 168.75 yuan, marking a five-year low [3]. - Yiling Pharmaceutical down over 3%, and Zhongsheng Pharmaceutical down over 2% [3]. - Conversely, stocks like Yunnan Baiyao and Jilin Aodong saw slight increases [3]. Valuation Metrics - As of December 3, the TTM price-to-earnings (PE) ratio for the ETF's index was 25.12, positioned at the 23.11% percentile over the past decade, suggesting that the index is cheaper than 76% of the time historically [5]. - The TTM PE is just 0.38 away from the calculated opportunity value, indicating a potential entry point for investors [5]. Historical Performance - The year-to-date return for the Chinese Medicine Index remains negative at -2.24%, with a decline of 8.13% projected for 2024 [7]. - The index has shown a pattern of consecutive declines, with four consecutive negative years if 2023 is considered a down year [7]. Demand Drivers - The recent flu outbreak has led to a significant increase in demand for respiratory medications, with flu cases reported rising by 53.8% compared to the previous week [9]. - The flu activity is at its highest level since 2022, which is expected to boost the demand for related medications [9]. Industry Outlook - Analysts from Zheshang Securities predict an inflection point for the Chinese medicine sector, suggesting that the sector will attract more investment due to its stable cash flow and lower volatility compared to other sectors [9]. - The industry is expected to see improved revenue and net profit growth in the second half of 2025, aided by reduced cost pressures from declining raw material prices [9].

Core Viewpoint - Darentang reported significant profit growth in Q3, with strong performance from its fast-acting heart rescue pill [1] Sales Performance - In the first three quarters, the sales revenue of the fast-acting heart rescue pill (including tax) reached 1.716 billion yuan, representing a year-on-year increase of 13.34% [1] - The sales revenue of the throat-soothing pill (including tax) was 376 million yuan, showing a year-on-year growth of 38.61% [1] Strategic Focus - The company is focusing on product and market strategies under brand leadership, enhancing regional coverage and channel penetration [1] - The emphasis on fast-acting products has led to good growth in key categories [1] Future Outlook - The company has streamlined its operations by divesting non-core businesses, which provides ample room for future development in pharmaceutical resource utilization and cost reduction [1] - The performance elasticity is expected to be promising [1] Investment Rating - The company maintains a "Buy" rating based on its strong performance and growth potential [1]

Core Viewpoint - The announcement highlights that Tianjin Yao Daren Tang Group Co., Ltd. has received a drug registration certificate for Loxoprofen Sodium Gel Patch, marking a significant milestone in the company's strategic layout in the transdermal drug delivery field [1][2]. Drug Registration Details - Drug Name: Loxoprofen Sodium Gel Patch - Dosage Form: Patch - Specification: Each patch (14cm×10cm) contains 10g of gel, with 100mg of Loxoprofen Sodium - Registration Category: Class 4 Chemical Drug - Approval Number: National Drug Approval H20255958 - The product is approved for domestic production and meets the relevant drug registration requirements [1][2]. Market Performance and Potential - Loxoprofen Sodium Gel Patch is used for inflammation and pain relief in conditions such as osteoarthritis and muscle pain, and it has been a leading analgesic in the Chinese market [2]. - According to data from the Minai database, the product has maintained a growth rate exceeding double digits in recent years, with projected national sales exceeding 1.7 billion yuan in 2024 and over 980 million yuan in the first half of 2025 [2]. Strategic Development - The company aims to establish a modern traditional Chinese medicine patch technology platform, integrating advanced technology with traditional medicine, and plans to build a product matrix covering chemical drugs, traditional Chinese medicine, and health patches [4]. - The approval of Loxoprofen Sodium Gel Patch signifies that the product has passed the consistency evaluation for generic drugs, although it is not expected to have a significant impact on the company's recent performance [4].

（文章来源：证券日报） 证券日报网讯 11月25日晚间，达仁堂发布公告称，公司所属分公司津药达仁堂集团股份有限公司新新 制药厂于近日收到国家药品监督管理局核准签发的洛索洛芬钠凝胶贴膏《药品注册证书》。 ...

分组1 - Weili Medical plans to distribute a cash dividend of 2 yuan per 10 shares to all shareholders, based on an undistributed profit of 704 million yuan as of September 30, 2025 [1] - Tongding Interconnect's shareholder plans to reduce their stake by up to 0.49%, equating to a maximum of 605,800 shares [1] - Caitong Securities has received approval from the China Securities Regulatory Commission to issue short-term corporate bonds with a total face value of up to 5 billion yuan [1] 分组2 - Youfu Food intends to use 70 million yuan of its own funds to invest in wealth management products with expected annual returns of up to 4.2% [3] - Keres received an administrative regulatory decision from the Guangdong Securities Regulatory Bureau for violations related to accounts receivable aging calculations and related party transactions [5] - Ouma Software's controlling shareholder has completed the transfer of state-owned equity, changing the controlling shareholder to Shandong Guotou [7] 分组3 - ST Huapeng's wholly-owned subsidiary has completed a major overhaul project and is now in production [8] - Beiqi Blue Valley has received approval from the China Securities Regulatory Commission for a stock issuance to specific investors [8] - Weijie Chuangxin received a government subsidy of 5 million yuan, accounting for 21.07% of its projected net profit for 2024 [9] 分组4 - China Resources Double Crane's subsidiary has received a drug registration certificate for a hypertension treatment drug [11] - Huafeng shares are continuing to suspend trading due to a planned change in control [13] - Kaifa Electric's shareholder plans to transfer 36.6869 million shares, representing 11.63% of the total share capital [14] 分组5 - Heng Rui Medicine has received approval for two clinical trials for innovative anti-tumor drugs [15] - Kosen Technology plans to invest 30 million USD to establish a new production base in Malaysia [17] - Sanxing Medical's subsidiary is expected to win a procurement project from the State Grid worth approximately 107 million yuan [18] 分组6 - Sitai Li's subsidiary has received a drug registration certificate for a contrast agent used in MRI [21] - Daren Tang's subsidiary has received a drug registration certificate for a pain relief gel [22] - Saike Xide has received approval for three medical device products, expanding its product range in the in vitro diagnostic field [23] 分组7 - Hasa Lian has elected a new chairman and vice chairman for its board of directors [24] - Two-sided Needle's subsidiary plans to invest 68.8522 million yuan in a production base expansion project [25] - Sunshine Nuohe plans to transfer 70% of its controlling subsidiary's equity for 2 million yuan [26] 分组8 - Hengbang shares received an administrative regulatory decision from the Shandong Securities Regulatory Bureau for failing to complete the election of independent directors [27] - Huali shares plan to sign a related transaction contract worth approximately 59.2847 million yuan [28] - Shangwei shares plan to invest 520.4 million yuan to gain a controlling stake in Sichuan Zhongfu Taihua [30] 分组9 - Zejing Pharmaceutical's ZG006 has been included in the list of breakthrough therapeutic varieties for treating advanced neuroendocrine cancer [32] - Yaopi Glass's shareholder plans to reduce their stake by up to 2.26%, equating to a maximum of 21.1469 million shares [34] - Huate Gas has initiated a major lawsuit involving a claim of 180 million yuan [36] 分组10 - Zhongchumei's controlling shareholder plans to increase their stake by between 42 million and 80 million yuan [37] - Huitong shares' shareholder plans to reduce their stake by up to 1% [38] - Miaowei Exhibition plans to apply for an initial public offering of H shares on the Hong Kong Stock Exchange [40] 分组11 - Tianqi Lithium's subsidiary has appealed to the Chilean Supreme Court regarding a partnership agreement with SQM and Codelco [42] - Naxin Micro plans to repurchase shares worth between 200 million and 400 million yuan [44] - Pingao shares have reported significant uncertainty regarding future business development and profitability [46] 分组12 - Shunyu shares have been pre-selected for a project worth 1.023 billion yuan [48] - Zhongyuan Neipei plans to acquire a 2.5% share in an aerospace industry fund for 50 million yuan [50] - Huifa Food's shareholder plans to reduce their stake by up to 3%, equating to a maximum of 727.14 million shares [53] 分组13 - Junshi Biosciences' subcutaneous PD-1 new formulation has reached its primary endpoint in a Phase III clinical trial [54] - Industrial Fulian clarified that it has not lowered its fourth-quarter profit target amid market rumors [55] - Longpan Technology's subsidiary has signed a major supply agreement for lithium iron phosphate materials, significantly increasing the supply volume [56]

证券代码：600329 证券简称：达仁堂 编号：临 2025-042 号 津药达仁堂集团股份有限公司 关于分公司获得药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 津药达仁堂集团股份有限公司（以下简称"公司"）所属分公司 津药达仁堂集团股份有限公司新新制药厂于近日收到国家药品监督 管理局核准签发的洛索洛芬钠凝胶贴膏《药品注册证书》，现将相关 情况公告如下： 一、药品注册证书的主要内容 药品名称：洛索洛芬钠凝胶贴膏 剂型：贴膏剂 规格：每贴（14cm×10cm）含膏量 10g，含洛索洛芬钠 100mg （C15H17NaO3计） 注册分类：化学药品 4 类 受理号：CYHS2401465、CYHB2501432 证书编号：2025S03428 上市许可持有人：津药达仁堂集团股份有限公司新新制药厂 生产企业：北京百奥药业有限责任公司 药品注册标准编号：YBH28222025 1 审批结论：根据《中华人民共和国药品管理法》及有关规定，经 审查，本品符合药品注册的有关要求，批准注册，发给药品注册证书。 质量标准、说 ...

Core Viewpoint - The company has received approval from the National Medical Products Administration for the registration of Loxoprofen Sodium Gel Patch, which is intended for the treatment of inflammation and pain associated with osteoarthritis, muscle pain, and post-injury swelling and pain [1] Group 1: Product Development - The approved product will serve as a starting point for the company to establish a modern traditional Chinese medicine patch technology platform that integrates research, production, and quality control [1] - The company aims to create a product matrix that covers chemical drugs, traditional Chinese medicine, and health patches, providing more medication options and improving patient experience [1] Group 2: Regulatory Approval - The Loxoprofen Sodium Gel Patch has been registered as a Class 4 chemical drug, and its approval is considered equivalent to passing the consistency evaluation [1] - The approval indicates that the product meets the relevant requirements for drug registration and is not expected to have a significant impact on the company's recent performance [1]

Core Viewpoint - Darentang (600329.SH) has received approval from the National Medical Products Administration for the registration of Loxoprofen Sodium Gel Patch, which is intended for the treatment of inflammation and pain associated with osteoarthritis, muscle pain, and post-injury swelling and pain [1] Group 1: Product Development - The company aims to establish a modern traditional Chinese medicine patch technology platform that integrates "R&D - production - quality control" capabilities [1] - The approval of Loxoprofen Sodium Gel Patch signifies that the product meets the relevant requirements for drug registration and will not have a significant impact on the company's recent performance [1] Group 2: Future Strategy - The company plans to continue building a product matrix that covers "chemical drugs - traditional Chinese medicine - health patches," providing more medication options and improving the medication experience for patients [1]

Group 1 - The core viewpoint of the news highlights the strong performance of the Traditional Chinese Medicine (TCM) sector, driven by supportive government policies aimed at innovation and industrial transformation [1][2] - The Shanghai government has issued a document encouraging collaboration among medical institutions, research units, and pharmaceutical companies to create platforms for TCM innovation and industrial transformation [1] - The document supports the development of major TCM varieties and the secondary development of classic varieties, as well as the establishment of mechanisms for collecting and organizing human experience data for drug registration [1] Group 2 - China Galaxy Securities anticipates that policy-driven changes will continue to propel the pharmaceutical industry towards innovation and upgrades, with a focus on finding incremental opportunities in niche markets [2] - The report indicates that domestic innovative drugs are expected to yield results, with several second-generation I/O drugs and ADCs entering phase three clinical trials, which is promising for future developments [2] - The TCM prescription drug market is facing clinical re-evaluation, which may reshape the market landscape and potentially lead to a turning point in TCM gross margins [2] Group 3 - The TCM ETF closely tracks the Zhongzheng TCM Index, which selects listed companies involved in TCM production and sales to reflect the overall performance of TCM concept stocks [2] - As of October 31, 2025, the top ten weighted stocks in the Zhongzheng TCM Index account for 54.92% of the index, including companies like Yunnan Baiyao and Tongrentang [2]

Core Viewpoint - The company will hold a performance briefing on December 2, 2025, to discuss its third-quarter results and address investor inquiries [3][4][8]. Group 1: Meeting Details - The meeting is scheduled for December 2, 2025, from 15:00 to 16:00 [2][4]. - It will be conducted online via Dongfang Caifu Roadshow [4][6]. - Investors can submit questions via email by November 28, 2025, at 17:00 [5][6]. Group 2: Participants - Key attendees include Chairwoman Wang Lei, CFO Ma Jian, an independent director representative, and Secretary of the Board Jiao Yan [4]. Group 3: Investor Participation - Investors can participate directly in the meeting on December 2, 2025, and the company will respond to questions within the scope of information disclosure [6][8]. - The meeting's proceedings and key content will be available for review on Dongfang Caifu Roadshow after the event [8].